Drug development: The use of unlicensed/off-label medicines in pediatrics

Journal of Pediatric Gastroenterology and Nutrition

Volumn 55, Issue 5, 2012, Pages 506-510

  Yamashiro, Yuichiro ^a   Martin, Jennifer ^b   Gazarian, Madlen ^c   Kling, Sharon ^d   Nakamura, Hidefumi ^e   Matsui, Akira ^e   Cucchiara, Salvatore ^f   Aloi, Marina ^f   Wynn, Erica L ^g   Mulberg, Andrew E ^g  

^a JUNTENDO UNIVERSITY   (Japan)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BERAPROST; CERTOLIZUMAB PEGOL; CHLORAL HYDRATE; DANTROLENE; ENALAPRIL MALEATE; HYDROCORTISONE; LISINOPRIL; METILDIGOXIN; PROPRANOLOL; RECOMBINANT TUMOR NECROSIS FACTOR; WARFARIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INFECTION; INJECTION SITE REACTION; LYMPHOMA; MEDICAL DECISION MAKING; NEOPLASM; OFF LABEL DRUG USE; PEDIATRICS; PRESCRIPTION; PRIORITY JOURNAL; TUBERCULOSIS;

CHILD; DRUG DISCOVERY; DRUG LABELING; HUMANS; LICENSURE; OFF-LABEL USE; PEDIATRICS;

EID: 84869089657     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318272af1f     Document Type: Article

References (42)

1. Baker R, Rosenthal P, Sherman P. Medication labelling for children: Where is it going? J Pediatr Gastroenterol Nutr 2002;35:111-2.
2. WHO. Better drugs for children. http://www.who.int
3. Gazarian M. Off-label use of medicines in the paediatric population: Recommendations for assessing appropriateness. http://archives.who. int/eml/expcom/children/INDEX-children-07-2.htm. Accessed July 22, 2012.
4. Turner S. Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm 1999;29:265-8.
5. Hoppu K, Anabwani G, Garcia-Bournissen F, et al. The status of paediatric medicines initiatives around the world - what has happened and what has not? Eur J Clin Pharmacol 2012;68:1-10.
6. Grieve J, Tordoff J, Reith D, et al. Effect of the pediatric exclusivity provision on children's access to medicines. Br J Clin Pharmacol 2005;59:730-5.
7. http://www.tga.gov.au.
8. Gazarian M. Why are children still therapeutic orphans? Aust Prescr 2003;22:122-3.
9. van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: A systematic review. Pediatrics 2011;127:925-35.
10. Harvey KJ, Faunce TA, Lokuge B, et al.Will the Australia-United States free trade agreement undermine the pharmaceutical benefits scheme? Med J Aust 2004;181:256-9.
11. Cohen SA, Lawson JA, Graudins LV, et al. Changes in anticonvulsant prescribing for Australian children: Implications for quality use of medicines. J Paediatr Child Health 2012;48:490-5.
12. Caviglia R, Boskoski I, Cicala M. Long-Term treatment with infliximab in inflammatory bowel disease: Safety and tolerability issues. Expert Opin Drug Saf 2008;7:617-32.
13. Parashette KR, Makam RC, Cuffari C. Infliximab therapy in pediatric Crohn's disease: A review. Clin Exp Gastroenterol 2010;3:57-63.
14. Gazarian M. Delivering better medicines to children: Need for better integration between the science, the policy, and the practice. Paediatr Drugs 2009;11:41-4.
15. Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: Consensus recommendations for evaluating appropriateness. Med J Aust 2006;185:544-8.
16. McLay JS, Tanaka M, Ekins-Daukes S, et al. A prospective questionnaire assessment of attitudes and experiences of off label prescribing among hospital based paediatricians. Arch Dis Child 2006;91:584-7.
17. Dick A, Keady S, Mohamed F, et al. Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment Pharmacol Ther 2003;17:571-5.
18. Palĉevski G, Skoĉibuŝić N, Vlahović- Palĉevski V. Unlicensed and offlabel drug use in hospitalized children in Croatia: A cross-sectional survey. Eur J Clin Pharmacol 2012;68:1073-7.
19. Bennett WM. Off-label use of approved drugs: Therapeutic opportunity and challenges. J Am Soc Nephrol 2004;15:830-1.
20. Choonara I, Conroy S. Unlicensed and off-label drug use in children. Drug Safety 2002;25:1-5.
21. Beggs SA, Cranswick NE, Reed MD. Improving drug use for children in the developing world. Arch Dis Child 2005;90:1091-3.
22. Steinbrook R. Testing medications in children. N Engl J Med 2002;347:1462-70.
23. Rocchi F, Tomasi P. The development of medicines for children. Pharmacol Res 2011;64:169-75.
24. Morita S. Prescription and package insert description analysis in paediatric drug use (in Japanese). 1999 MHLW Project Report for the Research on Current Status of the Off-label Use of Drugs in Children and Possible Solutions. Tokyo: Ministry of Health, Labour, andWelfare; 2000:52-99.
25. Li Z, Wang Y. Drug therapy for children in China. Pediatr Drugs 2009;11:16-7.
26. Park MS. Current status of pediatric pharmacology and development in Korea. Personalized Health Care for the Global Community. Past Present and Future (Program and Abstracts of the 2011 JSCPTKSCPT-ASCPTJoint Conference). 2011:38.
27. Kato Y. Survey of paediatric dosage form changes in Japan (in Japanese). 2005 MHLW Project Report for the Research on Data Network in Paediatric Drug Therapy. Tokyo: Ministry of Health, Labour, and Welfare; 2005:19-32.
28. Hoppu H, Anabwani G, Garcia-Bournissen F, et al. The status of paediatric drugs initiatives around the world-what has happened and what has not? Eur J Clin Pharmacol 2012;68:1-10.
29. Nakamura H, Ono S. Regulatory guidelines for pediatric drug development: Stimulation of pediatric drug research by regulatory authorities: Japanese perspective. In: Mulberg AE, Silber SA, van den Anker JN, eds. Pediatric Drug Development. Concepts and Applications. Hoboken: John Wiley & Sons; 2009:153-64.
30. Nahata MC. Lack of pediatric drug formulations. Pediatrics 1999; 104:607-9.
31. Remicade approved for children with Crohn's disease. FDA Consum 2006;40:6.
32. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-To-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
33. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391-9.
34. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012;143:365-74.
35. Mathis L, Vu H, Mulberg AE. Pediatric drug development: Unmet medical needs and opportunities for collaboration between industry, academia and the US FDA. Clin Invest 2011;1:1345-7.
36. Wilson JT. Pragmatic assessment of medicines available for young children and pregnant or breast-feeding women. Basic and Therapeutic Aspects of Perinatal Pharmacology. New York: Raven Press; 1975:411-21.
37. Sachs AN, Avant D, Lee CS, et al. Pediatric information in drug product labeling. JAMA 2012;307:1914-5.
38. Mulberg AE, ed. Pediatric Drug Development: Concepts and Applications. New York: Wiley-Blackwell; 2009.
39. Mulberg AE. Pharmaceutical industry in pediatric drug development: Partners and collaborators with academia and the FDA. J Pediatr Gastroenterol Nutr 2008;47:711-3.
40. Samir S, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007;1:282-90.
41. Bazzano ATF, Mangione-Smith R, Schonlau M, et al. Off-Label prescribing to children in the United States outpatient setting. Acad Pediatr 2009;9:81-8.
42. Liacouras CA, Furuta GT, Hirano IK, et al. Eosinophilic esophagitis: Updated recommendations for children and adults. J Allergy Clin Immunol 2011;128:3-20.